Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases that ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

Novo Nordisk partners with U.S. biotech Septerna in a $2.2 billion deal to develop oral small molecule drugs for obesity and ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

Novo Nordisk A/S is partnering with US biotech Septerna Inc. on the development of oral pills for obesity and type-2 diabetes ...

Reducing exposure to medicines is always a good thing if similar clinical outcomes can be achieved, and the study suggests it ...

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

As medications become increasingly popular to support weight loss, not all of them are approved by the U.S. Food and Drug Administration. Most prescription weight-loss drugs work by making you feel ...